Lung cancer vaccine trial begins in UK
A new lung cancer vaccine trial using mRNA technology has begun in the UK, involving 130 patients across seven countries. The BNT116 vaccine targets cancer cells, aiming to reduce side effects.
Read original article
A new lung cancer vaccine trial has commenced in the UK, with 67-year-old Janusz Racz being the first participant. This innovative treatment utilizes mRNA technology, similar to that used in COVID-19 vaccines, to instruct the immune system on how to identify and combat lung cancer cells. The early-stage trial aims to assess the vaccine's safety and will involve 130 patients across 34 research sites in seven countries, including the UK. The BNT116 vaccine, developed by BioNTech, is designed to specifically target cancer cells while minimizing damage to healthy cells, potentially reducing side effects. The trial will include patients with non-small cell lung cancer (NSCLC) at various stages, and the vaccine will be administered alongside standard treatments like immunotherapy and chemotherapy. NHS England's national cancer director highlighted the potential of such vaccines to revolutionize cancer treatment and provide hope for patients. The trial is part of a broader effort to explore mRNA technology in cancer therapies, with expectations of increased patient participation in future trials. Lung cancer remains the leading cause of cancer-related deaths globally, emphasizing the importance of innovative treatment options.
- A new lung cancer vaccine trial has started in the UK using mRNA technology.
- The trial aims to recruit 130 patients across 34 sites in seven countries.
- The BNT116 vaccine targets cancer cells specifically, potentially reducing side effects.
- The trial includes patients with various stages of non-small cell lung cancer.
- Experts believe this approach could revolutionize cancer treatment and improve patient outcomes.
Related
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
Nanorobot with hidden weapon kills cancer cells
Researchers at Karolinska Institutet developed nanorobots targeting cancer cells in mice. The nanorobots use a hidden weapon activated in acidic tumor environments, reducing tumor growth by 70% in tests. Further research is needed for human trials.
Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy, especially in glioblastoma cases, has shown significant progress. Mass General researchers use genetically modified white blood cells to target tumors, leading to rapid regression. This innovative approach offers hope for challenging cancer cases.
World-first mRNA lung cancer vaccine trials launched in seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116 in seven countries, targeting non-small cell lung cancer and aiming to improve patient survival rates.
1 commentsRelated
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
Nanorobot with hidden weapon kills cancer cells
Researchers at Karolinska Institutet developed nanorobots targeting cancer cells in mice. The nanorobots use a hidden weapon activated in acidic tumor environments, reducing tumor growth by 70% in tests. Further research is needed for human trials.
Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy, especially in glioblastoma cases, has shown significant progress. Mass General researchers use genetically modified white blood cells to target tumors, leading to rapid regression. This innovative approach offers hope for challenging cancer cases.
World-first mRNA lung cancer vaccine trials launched in seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116 in seven countries, targeting non-small cell lung cancer and aiming to improve patient survival rates.